Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D. Find out why REGN stock is a Buy.

Discover seven lung cancer companies advancing promising candidates through the clinic, from viral immunotherapies to ...

Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out as a therapy for another skin cancer called cutaneous squamous cell carcinoma (CSCC), and the rarity of that disease ...

Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year ...

TARRYTOWN, N.Y., May 01, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: REGN) today announced new and updated data from its oncology and hematology portfolio will be shared at the ...

Sanofi and Regeneron have reported new data for Libtayo that suggests the drug could be a contender. Overall survival (OS) was 22 months with the combination, compared to 13 months with chemo on ...

Replimune Group shares fell 28% on heavy volume with no news, despite a promising July 2025 PDUFA date for RP1 in advanced ...

Clinical Trial Supply Agreement Announced with Regeneron for Libtayo (cemiplimab): In February, Immuneering announced a clinical trial supply agreement with Regeneron Pharmaceuticals for its anti ...

MAIA Biotechnology, Inc. , a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that an abstract about the efficacy data from the Phase ...

Regeneron also purchased rights to the collaboration's PD-1 antibody Libtayo, which could serve as a foundation for future oncology combination regimens. Eylea has become the leading franchise in ...

We recently compiled a list of the 10 Jim Cramer Stocks with Huge Upside Potential. In this article, we are going to take a ...